ClinicalTrials.gg
TerminatedNCT02622724INTERESTUpdated Mar 30, 2020Results posted

Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Patients Having Acute Respiratory Distress Syndrome (ARDS)

A Phase 3 interventional study of Interferon beta-1a and Placebo in Respiratory Distress Syndrome, Adult, sponsored by Faron Pharmaceuticals Ltd. Terminated at 71 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-30.

Sponsored by Faron Pharmaceuticals Ltd · Phase 3, Interventional, and Treatment

Why this study was terminated
Day 90 results indicate IMP did not reduce mortality or ventilator free days

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
301
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 217 studies in Respiratory Distress Syndrome with a site in France — 42 open to participants now, 44 under way, 7 of them phase 3. Respiratory Distress Syndrome · France.

Enrollment
21st of 118
301 · median 50
Started
2015
with 7 others
Phase 3
25 of 217
7 open now
Registered
50th of 217
by date

Among the 217 studies in Respiratory Distress Syndrome with a site in France, this one is the 21st largest by enrollment of the 118 interventional ones that give a count, is one of 8 that started in 2015, is one of 25 in phase 3, and was the 50th registered.

Respiratory Distress Syndrome

1,387 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.

Browse Respiratory Distress Syndrome studies →

Open to participants now

42 of the 217 studies in Respiratory Distress Syndrome with a site in France are open now. Recruiting first, the newest first:

37 more — sign in →

All 42 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 193 Respiratory Distress Syndrome studies recruiting now, 117 (61%) set no upper age limit and 48 (25%) stop at 75 or younger; 50 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 217 studies in Respiratory Distress Syndrome with a site in France, or all of them as a file.
02

Study summary

In this study effectiveness and safety of a new drug FP-1201-lyo (recombinant human interferon beta-1a) is compared to placebo. Investigation is conducted with patients who have acute respiratory distress syndrome (ARDS). The new drug is expected to reduce the time which a patient need to be on the ventilator and improve patient's chances of survival. Currently there are no approved drugs for treating moderate or severe ARDS patients.

Read the detailed description

This is a Phase III clinical study to investigate the efficacy and safety of FP-1201-lyo (recombinant human interferon [IFN] beta-1a) compared to placebo in patients diagnosed with moderate or severe acute respiratory distress syndrome (ARDS). Primary objective is to demonstrate the efficacy of FP-1201-lyo in improving the clinical course and outcome based on survival and need for mechanical ventilation. Currently there are no approved drugs for treating moderate or severe ARDS patients.

FP-1201-lyo is a lyophilised powder form of recombinant human IFN beta-1a reconstituted in water for injection and is administered intravenously.

Recombinant human IFN beta-1a is an approved treatment for patients for other indication and its safety profile in such patients is well characterised.

03

Conditions studied

  • Respiratory Distress Syndrome, Adult

Keywords

  • ARDS, human
  • Acute Respiratory Distress Syndrome
  • Respiratory Insufficiency
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All patients must be intubated and mechanically ventilated to diagnose ARDS and be eligible for the study

  1. Patient has a diagnosis of moderate or severe ARDS according to the Berlin definition of ARDS:

    • Acute onset of respiratory failure within 1 week of a known clinical insult or new or worsening respiratory symptoms
    • Respiratory failure associated with known ARDS risk factors and not fully explained by either cardiac failure or fluid overload (an objective assessment of cardiac failure or fluid overload is needed if no risk factors for ARDS [moderate or severe ARDS] are present)
    • Radiological abnormalities on chest X-ray or on computerised tomography scan, i.e., bilateral opacities that are not fully explained by effusions, nodules, masses or lobar/lung collapse
    • Hypoxaemia:

      • Moderate ARDS: PaO2/FiO2 >100 mmHg (>13.3 kPa) to ≤200 mmHg (≤26.6 kPa) with positive end expiratory pressure (PEEP) ≥5 cmH2O
      • Severe ARDS: PaO2/FiO2 ≤100 mmHg (≤13.3 kPa) with positive end expiratory pressure [PEEP] ≥5 centimeter of water [cmH2O]
  2. The radiological and hypoxaemia criteria (1.3 and 1.4) must be met within the same 24-hour period. The time of onset of ARDS is when the last of the two specified ARDS criteria is met
  3. Administration of the first dose of study drug must be planned to take place within 48 hours of moderate or severe ARDS diagnosis
  4. Patient is intubated and mechanically ventilated
  5. A signed form from the patient or the patient's personal legal representative or a professional legal representative must be available
  6. Patient is aged ≥18 years

Exclusion criteria

Exclusion Criteria:

  1. Woman known to be pregnant, lactating or with a positive (urine or serum test) or indeterminate (serum test) pregnancy test
  2. Patient is simultaneously taking part in another pharmacotherapy protocol
  3. Patient is not expected to survive for 24 hours
  4. Patient has an underlying clinical condition where, in the opinion of the Investigator, it would be extremely unlikely that the patient would come off ventilation, e.g., motor neurone disease, Duchenne muscular dystrophy or rapidly progressive interstitial pulmonary fibrosis
  5. Patient has severe requiring long-term home oxygen therapy or mechanical ventilation (non-invasive ventilation or via tracheotomy) except for continuous positive airway pressure (CPAP) or bi-level positive airway pressure used solely for sleep-disordered breathing
  6. Patient has congestive heart failure, defined as class IV
  7. Patient has acute left ventricular failure
  8. Patient has liver failure ( grade C)
  9. Patient has received any prior interferon
  10. Patient has known to natural or recombinant IFN beta or to any of the
  11. Patient is receiving renal dialysis therapy for chronic renal failure
  12. Patient is receiving extra-corporeal membrane oxygenation, high-frequency oscillatory ventilation or any form of extra-corporeal lung support
  13. Patient has had any form of mechanical ventilation (invasive or non-invasive, excluding CPAP alone) for longer than 48 hours prior to the diagnosis of ARDS. Non-invasive ventilation has to be continuously applied for at least 12 hours per day in these 48 hours
  14. Patient has burns to ≥15% of their total body surface area
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
301 participants (actual)

Study arms

  • Experimental
    FP-1201-lyo 10 μg

    FP-1201-lyo 10 μg (Interferon beta-1a) will be administered once daily as an intravenous bolus injection for 6 days. Investigational product is lyophilisate for solution for injection which will be reconstituted in water for injection.

    Drug: Interferon beta-1a

  • Placebo comparator
    FP-1201-lyo Placebo

    FP-1201-lyo Placebo will be administered once daily as an intravenous bolus injection for 6 days. Investigational placebo product is lyophilisate for solution for injection which will be reconstituted in water for injection.

    Drug: Placebo

Interventions

  • Investigational drug

    Also known as: FP-1201-lyo, Traumakine, ATC code L03AB07

  • DrugPlacebo

    Placebo for investigational drug

    Also known as: FP-1201-lyo Placebo

06

What researchers measure

Primary outcomes

  1. Composite Endpoint (VFDsurv; All-cause Mortality and Number of Days Free of Mechanical Ventilation) at Day 28

    VFDsurv is a composite measure of all-cause mortality and the number of days free of mechanical ventilation (VFDsurv) within 28 days among survivors. Ventilator-free days (VFDs) correspond to those days when unassisted breathing (UAB) was possible for a complete calendar day. UAB was defined as: spontaneously breathing with face mask, nasal prong oxygen or room air, T-piece breathing, tracheostomy mask breathing, CPAP less than or equal to 5 cmH2O without pressure support or intermittent mandatory ventilation assistance, use of CPAP or BIPAP solely for sleep apnoea management. A patient was reported as ventilator-free after 2 consecutive calendar days of unassisted breathing (a VFD value of 0 is assigned to patients who die without initiating UAB or who require more than 28 days of mechanical ventilation. All patients who die before Day28 are assigned a VFDsurv value of -1).

    Time frame: Day 28

Secondary outcomes

  1. Efficacy Endpoint: All-cause Mortality

    Fatalities, mortality all-causes from randomisation up to Day 28

    Time frame: At Day 28

  2. Efficacy Endpoint: Mortality in ICU

    All-cause mortality for subjects who died in Intensive Care Units up to Day 28.

    Time frame: Up to Day 28

  3. Efficacy Endpoint: Mortality in Hospital

    This is the number of subjects who died in hospital (i.e. outside of Intensive Care Units) up to Day 28.

    Time frame: Up to Day 28

  4. Other Secondary Efficacy Endpoints: Days Free of Organ Failure

    The total number of days free of organ failure by Sequential Organ Failure Assessment (SOFA) methodology. Overall, the median number of days free of organ failure was 0 days in both the treatment groups.

    Time frame: Day 28 or last day in intensive care unit [ICU] if patient has left the ICU earlier than Day 28

  5. Other Secondary Efficacy Endpoints: Days Free of Renal Support

    Days without renal support (any renal support was documented). Overall, the median number of days free of renal support was 28 days in the active group and 27 days in the placebo group.

    Time frame: Day 28

  6. Other Secondary Efficacy Endpoints: Days Free of Vasoactive Support

    Days without vasoactive support. The vasoactive support included catecholamine and non-catecholamine vasopressors, inotropes and vasodilating agents. Overall, the median number of days free of vasoactive support was 20 days in the active group and 21 days in the placebo group.

    Time frame: Day 28

  7. Other Secondary Efficacy Endpoint: Days Free of Mechanical Ventilation

    The total number of days free of mechanical ventilation has been derived from the Patient Status report recorded on each day during the 28-day period. Patients who died during this period have been assigned a value of zero. This variable differs from the calculated "Ventilation Free Days (VFD) endpoint, which contribute to the VDFsurv primary efficacy endpoint as it require additional conditions of unassisted breathing (UAB) to be met.

    Time frame: Day 28

  8. Other Secondary Efficacy Endpoints: Number of ICU-free Days

    Number of Intensive Care Unit free days up to Day 28, i.e. the patient is no longer receiving care in ICU. Patients who die during this period have been assigned a value of zero for the number of ICU care free days.

    Time frame: Day 28

  9. Other Secondary Efficacy Endpoints: Number of Days in Hospital

    Hospitalisation days (including the stay at Intensive Care Units). Patients who died during this period have been assigned a value of 28 for the number of days in ICU or in hospital.

    Time frame: Day 28

  10. Evaluation of Safety: Adverse Events and Deaths

    Adverse events (AE) up to Day 28. Per protocol, AEs occurring after Day 28 if the investigator considered a causal relationship with the study drug as well as all deaths up to Day 360 were reported. Treatment-emergent AEs (TEAEs) were defined as AEs that begins or worsens in intensity after at least one dose of study drug has been administered. Serious AEs (SAEs) were defined as any untoward medical occurrence that at any dose resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; was an important medical event.

    Time frame: AEs up to Day 28, only related after Day 28 and deaths up to Day 360

  11. Efficacy Endpoint: Presence of Neutralising Antibodies to IFN Beta-1a

    The immunological response to FP-1201-lyo was assessed by monitoring presence of anti-drug binding antibodies (BAbs) and neutralising antibodies (NAbs) to IFN beta-1a on pre-dose Day 1 and at Day 28, the last day in ICU or early termination (if earlier). The BAbs were determined first, and if present, the NAbs were also determined. Presence of BAbs and NAbs were summarised categorically, using positive/negative classification.

    Time frame: Baseline and Day 28 (or last day in intensive care unit [ICU] or at withdrawal, if earlier)

  12. Efficacy Endpoint: Evaluation of Pharmacodynamic (PD) Using Myxovirus Resistance Protein A (MxA) Biomarker

    Evaluation of MxA biomarker change from baseline to D14 between treatments arms over time.

    Time frame: From baseline to Day 14

  13. Long-term Efficacy Endpoint: Change in Quality of Life From Baseline to Day 180

    Quality of Life was assessed through EQ-5D-3L (EuroQol 5-Dimensions 3-Levels questionnaire). An EQ Visual Analogue Scale (VAS) total score (ranging from 0-100) was measured (0= Worst imaginable health state, 100= Best imaginable health state). The EQ-5D-3L VAS scores are numerically summarised as change from pre-dose (Day 1) to long term follow-up (Day 180 visit).

    Time frame: Change from baseline to Day 180

  14. Long-term Efficacy Endpoints Relating to Respiratory Functioning (FEV1)

    Measuring FEV1 (forced expiratory volume in 1 second) assessed pulmonary function (airway obstruction, bronchoconstriction or bronchodilation). FEV1 is the volume exhaled during the first second of a forced expiratory manoeuvre, starting from the level of total lung capacity.

    Time frame: Day 180

  15. Long-term Efficacy Endpoints Relating to Neurological Functioning (6MWT)

    The 6-minute walk test (6MWT) measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes. According to the ERS/ATS technical standard to which the 6MWT was done, the walk test is done twice and the best result is used. It is an evaluation of the global and integrated responses of all systems involved during exercise, including the pulmonary and cardiovascular systems, systemic circulation, peripheral circulation, blood and neuromuscular units and muscle metabolism. The self-paced 6MWT assesses the sub- maximal level of functional capacity and will better reflect the functional exercise level for daily activities. ANOVA parameters estimates (LS Means and 90 % conf.interval) for the overall treatment difference was analysed.

    Time frame: Day 180

Other outcomes

  1. Evaluation of Safety: Vital Signs - Heart Rate

    Vital signs were measured supine pre-dose on Day 1 (baseline) and daily up to Day 28 while the patient was in the ICU. The results at baseline and at last observation performed (LOP) were summarized overall by treatment, variable and time point. No statistical analyses were made for vital signs.

    Time frame: From baseline to Last Observation Performed (Day 28 or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)

  2. Evaluation of Safety: Vital Signs - Body Temperature

    Vital signs were measured supine pre-dose on Day 1 (baseline) and daily up to Day 28 while the patient was in the ICU. The results at baseline and at last observation performed (LOP) were summarized overall by treatment, variable and time point. No statistical analyses were made for vital signs.

    Time frame: From baseline to Last Observation Performed (Day 28 or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)

  3. Evaluation of Safety: Vital Signs - Blood Pressure

    Vital signs were measured supine pre-dose on Day 1 (baseline) and daily up to Day 28 while the patient was in the ICU. The results at baseline and at last observation performed (LOP) were summarized overall by treatment, variable and time point. No statistical analyses were made for vital signs.

    Time frame: From baseline to Last Observation Performed (Day 28 or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)

  4. Evaluation of Safety: Physical Examination

    Physical examination data (covering the major body systems; general appearance, head \[ear, nose and throat\], cardiovascular, eyes, respiratory, abdomen, urogenital, musculoskeletal, neurological, lymph nodes and skin) were categorized as "normal"; "abnormal, not clinically significant;" "abnormal, clinically significant" or "not done". Physical examinations were performed at Screening, then at the Last day in ICU and Day 28 (Out of ICU) or Early Termination, from which the last observation performed is derived. The changes from baseline to the last observations performed are categorized as "no change", "change clinically significant"; "change not clinically significant", "not done".

    Time frame: From baseline to Last Observation Performed (D28 or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)

  5. Evaluation of Safety: Laboratory Results

    Laboratory safety assessments of biochemistry, haematology and urinalysis were performed daily during the stay at ICU. Laboratory data were classified according to normal ranges as out of range (OOR; not clinically significant), OOR (clinically significant), or OOR (clinically significant and an AE). Laboratory test results were summarised by actual results by baseline and last observation period.

    Time frame: From baseline to Day 28 (or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)

  6. Evaluation of Pharmacoeconomics: Days Free of Organ Failure

    Due to the study terminating early, costs items from hospitals were not collected and pharmacoeconomic analyses could not be done.

    Time frame: Day 28 (or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)

  7. Evaluation of Pharmacoeconomics: Days Free of Renal Support

    Due to the study terminating early, costs items from hospitals were not collected and pharmacoeconomic analyses could not be done.

    Time frame: Day 28 (or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)

  8. Evaluation of Pharmacoeconomics: Days Free of Vasoactive Support

    Due to the study terminating early, costs items from hospitals were not collected and pharmacoeconomic analyses could not be done.

    Time frame: Day 28 (or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)

  9. Evaluation of Pharmacoeconomics: Days Free of Mechanical Ventilation

    Due to the study terminating early, costs items from hospitals were not collected and pharmacoeconomic analyses could not be done.

    Time frame: Day 28 (or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)

  10. Evaluation of Pharmacoeconomics: Number of ICU-free Days

    Due to the study terminating early, costs items from hospitals were not collected and pharmacoeconomic analyses could not be done.

    Time frame: Day 28 (or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)

  11. Evaluation of Pharmacoeconomics: Number of Days in Hospital

    Due to the study terminating early, costs items from hospitals were not collected and pharmacoeconomic analyses could not be done.

    Time frame: Day 28 (or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)

  12. Exploratory Variables Relating to Efficacy: Composite Endpoint (Mortality and Days Free of Mechanical Ventilation) at Day 90

    Composite endpoint including mortality and days free of mechanical ventilation (VFDsurv) within 90 days among survivors. Ventilation Free Survival at Day 90 has been classified as Dead, Alive but on a ventilator and Alive and breathing unassisted

    Time frame: Within 90 days

  13. Change in the Treatment-specific Exploratory Biomarker Cluster of Differentiation 73 (CD73) Concentration

    Evaluation of Cluster of differentiation 73 (CD73) change from baseline to D14 between treatments arms over time.

    Time frame: From baseline to Day 14

  14. Changes in Levels of Potential Inflammatory Markers (PIMs)

    Evaluation of potential inflammatory markers (PIMs) change from baseline to D14 between treatments arms over time. Potential biomarkers included IL-1ra, IL-6, FGF basic, IP-10 and TNF-α.

    Time frame: From baseline to Day 14

  15. Pharmacogenetic Analysis

    An optional genetic sample was analysed for subjects based on a separate consent. A carrier frequency was analysed for a C/T polymorphism (rs9984723) located in the 3'PRIME_UTR/intron region of IFNAR2-gene, which encodes the beta chain for the IFN-alpha/beta receptor and encompasses a regulatory motif for the glucocorticoid receptor. Biomarker responders were defined by a 3-fold elevation in MxA and a 2-fold in CD73 in comparison to baseline.

    Time frame: Anytime from baseline to Day 28

  16. Exploratory, Extended Long-term Follow-up: Overall Mortality at Day 360

    Fatalities; as the study was terminated early, the assessment time point for mortality at Day 360 was not reached. Therefore only the overall mortality at study termination is presented.

    Time frame: Day 360 /termination of study

  17. Extended Long-term Follow-up Exploratory Endpoint: Change in Quality of Life From Baseline to Day 360

    Quality of Life was assessed through EQ-5D-3L (EuroQol 5-Dimensions 3-Levels questionnaire). An EQ Visual Analogue Scale (VAS) total score (ranging from 0-100) was measured (0= Worst imaginable health state, 100= Best imaginable health state). The EQ-5D-3L VAS scores are numerically summarised as change from pre-dose (Day 1) to extended long term follow-up (Day 360 visit).

    Time frame: Change from baseline to Day 360

  18. Neurological Functioning (6MWT) at Extended Long-term Follow-up

    The 6-minute walk test (6MWT) measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes. According to the ERS/ATS technical standard to which the 6MWT was done, the walk test is done twice and the best result is used. It is an evaluation of the global and integrated responses of all systems involved during exercise, including the pulmonary and cardiovascular systems, systemic circulation, peripheral circulation, blood and neuromuscular units and muscle metabolism. The self-paced 6MWT assesses the sub- maximal level of functional capacity and will better reflect the functional exercise level for daily activities. ANOVA parameters estimates (LS Means and 90 % confidence intervals) for the overall treatment difference was analysed.

    Time frame: Day 360

  19. Extended Long-term Follow-up Endpoint: Respiratory Functioning (FEV1) at Day 360

    Measuring FEV1 (forced expiratory volume in 1 second) assessed pulmonary function (airway obstruction, bronchoconstriction or bronchodilation). FEV1 is the volume exhaled during the first second of a forced expiratory manoeuvre, starting from the level of total lung capacity.

    Time frame: Day 360

07

Results

Posted Mar 30, 2020
Limitations and caveats
As the study was terminated early, only a limited amount of data was available at Day 180 and Day 360.

Participant flow

Participant flow — Overall Study
MilestoneFP-1201-lyo 10 μgPlacebo
Started144152
Subjects randomised146155
Short-term follow-up (day 28)105115
Long-term follow-up (day 90)96101
Long-term follow-up (day 180)7374
Completed5149
Not completed93103
Withdrew: Death5153
Withdrew: Lost to follow-up, withdrawal of consent47
Withdrew: Early termination of study3843

Outcome measures

PrimaryComposite Endpoint (VFDsurv; All-cause Mortality and Number of Days Free of Mechanical Ventilation) at Day 28

VFDsurv is a composite measure of all-cause mortality and the number of days free of mechanical ventilation (VFDsurv) within 28 days among survivors. Ventilator-free days (VFDs) correspond to those days when unassisted breathing (UAB) was possible for a complete calendar day. UAB was defined as: spontaneously breathing with face mask, nasal prong oxygen or room air, T-piece breathing, tracheostomy mask breathing, CPAP less than or equal to 5 cmH2O without pressure support or intermittent mandatory ventilation assistance, use of CPAP or BIPAP solely for sleep apnoea management. A patient was reported as ventilator-free after 2 consecutive calendar days of unassisted breathing (a VFD value of 0 is assigned to patients who die without initiating UAB or who require more than 28 days of mechanical ventilation. All patients who die before Day28 are assigned a VFDsurv value of -1).

Time frame:
Day 28
Reported as:
Median · Days
Composite Endpoint (VFDsurv; All-cause Mortality and Number of Days Free of Mechanical Ventilation) at Day 28
DaysFP-1201-lyo 10 μgPlacebo
Composite Endpoint (VFDsurv; All-cause Mortality and Number of Days Free of Mechanical Ventilation) at Day 2810 (-1 to 26)8.5 (-1 to 26)
Statistical analysis
  • FP-1201-lyo 10 μg vs Placebo · Van Elteren hypothesis test · p = 0.8219
SecondaryEfficacy Endpoint: All-cause Mortality

Fatalities, mortality all-causes from randomisation up to Day 28

Time frame:
At Day 28
Reported as:
Number · percentage of subjects
Efficacy Endpoint: All-cause Mortality
percentage of subjectsFP-1201-lyo 10 μgPlacebo
Efficacy Endpoint: All-cause Mortality26.4 (19 to 34)23 (17 to 31)
SecondaryEfficacy Endpoint: Mortality in ICU

All-cause mortality for subjects who died in Intensive Care Units up to Day 28.

Time frame:
Up to Day 28
Reported as:
Number · percentage of subjects
Efficacy Endpoint: Mortality in ICU
percentage of subjectsFP-1201-lyo 10 μgPlacebo
Efficacy Endpoint: Mortality in ICU25.7 (19 to 34)23.0 (17 to 31)
SecondaryEfficacy Endpoint: Mortality in Hospital

This is the number of subjects who died in hospital (i.e. outside of Intensive Care Units) up to Day 28.

Time frame:
Up to Day 28
Reported as:
Count of participants · Participants
Efficacy Endpoint: Mortality in Hospital
ParticipantsFP-1201-lyo 10 μgPlacebo
Efficacy Endpoint: Mortality in Hospital10
SecondaryOther Secondary Efficacy Endpoints: Days Free of Organ Failure

The total number of days free of organ failure by Sequential Organ Failure Assessment (SOFA) methodology. Overall, the median number of days free of organ failure was 0 days in both the treatment groups.

Time frame:
Day 28 or last day in intensive care unit [ICU] if patient has left the ICU earlier than Day 28
Reported as:
Median · Days
Other Secondary Efficacy Endpoints: Days Free of Organ Failure
DaysFP-1201-lyo 10 μgPlacebo
Other Secondary Efficacy Endpoints: Days Free of Organ Failure0 (0 to 28)0 (0 to 28)
SecondaryOther Secondary Efficacy Endpoints: Days Free of Renal Support

Days without renal support (any renal support was documented). Overall, the median number of days free of renal support was 28 days in the active group and 27 days in the placebo group.

Time frame:
Day 28
Reported as:
Median · Days
Other Secondary Efficacy Endpoints: Days Free of Renal Support
DaysFP-1201-lyo 10 μgPlacebo
Other Secondary Efficacy Endpoints: Days Free of Renal Support28 (0 to 28)27 (0 to 28)
SecondaryOther Secondary Efficacy Endpoints: Days Free of Vasoactive Support

Days without vasoactive support. The vasoactive support included catecholamine and non-catecholamine vasopressors, inotropes and vasodilating agents. Overall, the median number of days free of vasoactive support was 20 days in the active group and 21 days in the placebo group.

Time frame:
Day 28
Reported as:
Median · Days
Other Secondary Efficacy Endpoints: Days Free of Vasoactive Support
DaysFP-1201-lyo 10 μgPlacebo
Other Secondary Efficacy Endpoints: Days Free of Vasoactive Support20 (0 to 28)21 (1 to 28)
SecondaryOther Secondary Efficacy Endpoint: Days Free of Mechanical Ventilation

The total number of days free of mechanical ventilation has been derived from the Patient Status report recorded on each day during the 28-day period. Patients who died during this period have been assigned a value of zero. This variable differs from the calculated "Ventilation Free Days (VFD) endpoint, which contribute to the VDFsurv primary efficacy endpoint as it require additional conditions of unassisted breathing (UAB) to be met.

Time frame:
Day 28
Reported as:
Median · Days
Other Secondary Efficacy Endpoint: Days Free of Mechanical Ventilation
DaysFP-1201-lyo 10 μgPlacebo
Other Secondary Efficacy Endpoint: Days Free of Mechanical Ventilation10 (0 to 26)9 (0 to 26)
Statistical analysis
  • FP-1201-lyo 10 μg vs Placebo · Van Elteren p-values · p = 0.4678
SecondaryOther Secondary Efficacy Endpoints: Number of ICU-free Days

Number of Intensive Care Unit free days up to Day 28, i.e. the patient is no longer receiving care in ICU. Patients who die during this period have been assigned a value of zero for the number of ICU care free days.

Time frame:
Day 28
Reported as:
Median · Days
Other Secondary Efficacy Endpoints: Number of ICU-free Days
DaysFP-1201-lyo 10 μgPlacebo
Other Secondary Efficacy Endpoints: Number of ICU-free Days6 (0 to 24)3.5 (0 to 24)
SecondaryOther Secondary Efficacy Endpoints: Number of Days in Hospital

Hospitalisation days (including the stay at Intensive Care Units). Patients who died during this period have been assigned a value of 28 for the number of days in ICU or in hospital.

Time frame:
Day 28
Reported as:
Median · Days
Other Secondary Efficacy Endpoints: Number of Days in Hospital
DaysFP-1201-lyo 10 μgPlacebo
Other Secondary Efficacy Endpoints: Number of Days in Hospital28 (8 to 28)28 (8 to 28)
SecondaryEvaluation of Safety: Adverse Events and Deaths

Adverse events (AE) up to Day 28. Per protocol, AEs occurring after Day 28 if the investigator considered a causal relationship with the study drug as well as all deaths up to Day 360 were reported. Treatment-emergent AEs (TEAEs) were defined as AEs that begins or worsens in intensity after at least one dose of study drug has been administered. Serious AEs (SAEs) were defined as any untoward medical occurrence that at any dose resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; was an important medical event.

Time frame:
AEs up to Day 28, only related after Day 28 and deaths up to Day 360
Reported as:
Count of participants · Participants
Evaluation of Safety: Adverse Events and Deaths
ParticipantsFP-1201-lyo 10 μgPlacebo
Subjects with TEAE130132
Subjects with AE considered related to study drug4133
Subjects with SAE7777
Death5153
SecondaryEfficacy Endpoint: Presence of Neutralising Antibodies to IFN Beta-1a

The immunological response to FP-1201-lyo was assessed by monitoring presence of anti-drug binding antibodies (BAbs) and neutralising antibodies (NAbs) to IFN beta-1a on pre-dose Day 1 and at Day 28, the last day in ICU or early termination (if earlier). The BAbs were determined first, and if present, the NAbs were also determined. Presence of BAbs and NAbs were summarised categorically, using positive/negative classification.

Time frame:
Baseline and Day 28 (or last day in intensive care unit [ICU] or at withdrawal, if earlier)
Reported as:
Count of participants · Participants
Efficacy Endpoint: Presence of Neutralising Antibodies to IFN Beta-1a
ParticipantsFP-1201-lyo 10 μgPlacebo
Presence of BAbs to IFN β-1a at baseline22
Presence of BAbs to IFN β-1a at Day2801
Presence of NAbs to IFN β-1a at baseline10
Presence of NAbs to IFN β-1a at Day2800
SecondaryEfficacy Endpoint: Evaluation of Pharmacodynamic (PD) Using Myxovirus Resistance Protein A (MxA) Biomarker

Evaluation of MxA biomarker change from baseline to D14 between treatments arms over time.

Time frame:
From baseline to Day 14
Reported as:
Mean · ng/ml
Efficacy Endpoint: Evaluation of Pharmacodynamic (PD) Using Myxovirus Resistance Protein A (MxA) Biomarker
ng/mlFP-1201-lyo 10 μgPlacebo
Efficacy Endpoint: Evaluation of Pharmacodynamic (PD) Using Myxovirus Resistance Protein A (MxA) Biomarker31.8 ± 63.37.8 ± 28.8
Statistical analysis
  • FP-1201-lyo 10 μg · ANCOVA · p = <0.05Analysis of covariance (ANCOVA) model using Type III sums of squares with Treatment, Severity, and Country fixed effect factors, Baseline as covariate
SecondaryLong-term Efficacy Endpoint: Change in Quality of Life From Baseline to Day 180

Quality of Life was assessed through EQ-5D-3L (EuroQol 5-Dimensions 3-Levels questionnaire). An EQ Visual Analogue Scale (VAS) total score (ranging from 0-100) was measured (0= Worst imaginable health state, 100= Best imaginable health state). The EQ-5D-3L VAS scores are numerically summarised as change from pre-dose (Day 1) to long term follow-up (Day 180 visit).

Time frame:
Change from baseline to Day 180
Reported as:
Median · change score on a scale
Long-term Efficacy Endpoint: Change in Quality of Life From Baseline to Day 180
change score on a scaleFP-1201-lyo 10 μgPlacebo
Long-term Efficacy Endpoint: Change in Quality of Life From Baseline to Day 180-10 (-55 to 70)-5 (-60 to 91)
SecondaryLong-term Efficacy Endpoints Relating to Respiratory Functioning (FEV1)

Measuring FEV1 (forced expiratory volume in 1 second) assessed pulmonary function (airway obstruction, bronchoconstriction or bronchodilation). FEV1 is the volume exhaled during the first second of a forced expiratory manoeuvre, starting from the level of total lung capacity.

Time frame:
Day 180
Reported as:
Mean · %FEV1
Long-term Efficacy Endpoints Relating to Respiratory Functioning (FEV1)
%FEV1FP-1201-lyo 10 μgPlacebo
Long-term Efficacy Endpoints Relating to Respiratory Functioning (FEV1)81.2 ± 21.179.5 ± 29.6
SecondaryLong-term Efficacy Endpoints Relating to Neurological Functioning (6MWT)

The 6-minute walk test (6MWT) measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes. According to the ERS/ATS technical standard to which the 6MWT was done, the walk test is done twice and the best result is used. It is an evaluation of the global and integrated responses of all systems involved during exercise, including the pulmonary and cardiovascular systems, systemic circulation, peripheral circulation, blood and neuromuscular units and muscle metabolism. The self-paced 6MWT assesses the sub- maximal level of functional capacity and will better reflect the functional exercise level for daily activities. ANOVA parameters estimates (LS Means and 90 % conf.interval) for the overall treatment difference was analysed.

Time frame:
Day 180
Reported as:
Mean · maximum distance walked (meters)
Long-term Efficacy Endpoints Relating to Neurological Functioning (6MWT)
maximum distance walked (meters)FP-1201-lyo 10 μgPlacebo
Long-term Efficacy Endpoints Relating to Neurological Functioning (6MWT)449 ± 174424 ± 156
Statistical analysis
  • FP-1201-lyo 10 μg vs Placebo · ANOVA · p = >0.05 · Least squares mean: 31.1 · 95% CI -37.7 to 99.9
Other pre-specifiedEvaluation of Safety: Vital Signs - Heart Rate

Vital signs were measured supine pre-dose on Day 1 (baseline) and daily up to Day 28 while the patient was in the ICU. The results at baseline and at last observation performed (LOP) were summarized overall by treatment, variable and time point. No statistical analyses were made for vital signs.

Time frame:
From baseline to Last Observation Performed (Day 28 or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)
Reported as:
Mean · bpm
Evaluation of Safety: Vital Signs - Heart Rate
bpmFP-1201-lyo 10 μgPlacebo
Heart Rate, bpm : Pre-Dose93.4 ± 22.294.8 ± 22.5
Heart Rate, bpm : LOP92.5 ± 18.392.7 ± 19.0
Other pre-specifiedEvaluation of Safety: Vital Signs - Body Temperature

Vital signs were measured supine pre-dose on Day 1 (baseline) and daily up to Day 28 while the patient was in the ICU. The results at baseline and at last observation performed (LOP) were summarized overall by treatment, variable and time point. No statistical analyses were made for vital signs.

Time frame:
From baseline to Last Observation Performed (Day 28 or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)
Reported as:
Mean · degrees Celsius
Evaluation of Safety: Vital Signs - Body Temperature
degrees CelsiusFP-1201-lyo 10 μgPlacebo
Body Temperature, degrees C : Pre-Dose37.1 ± 1.137.2 ± 1.1
Body Temperature, degrees C : LOP36.9 ± 0.936.8 ± 0.7
Other pre-specifiedEvaluation of Safety: Vital Signs - Blood Pressure

Vital signs were measured supine pre-dose on Day 1 (baseline) and daily up to Day 28 while the patient was in the ICU. The results at baseline and at last observation performed (LOP) were summarized overall by treatment, variable and time point. No statistical analyses were made for vital signs.

Time frame:
From baseline to Last Observation Performed (Day 28 or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)
Reported as:
Mean · mmHg
Evaluation of Safety: Vital Signs - Blood Pressure
mmHgFP-1201-lyo 10 μgPlacebo
Systolic Blood Pressure, mmHg: Pre-Dose114.6 ± 20.4110.2 ± 18.0
Systolic Blood Pressure, mmHg : LOP124.3 ± 22.8120.3 ± 26.2
Diastolic Blood Pressure, mmHg : Pre-Dose58.9 ± 12.955.6 ± 9.7
Diastolic Blood Pressure, mmHg : LOP65.1 ± 14.862.6 ± 13.8
Mean Arterial Pressure, mmHg : Pre-Dose76.5 ± 13.973.6 ± 11.2
Mean Arterial Pressure, mmHg : LOP82.7 ± 15.580.8 ± 16.6
Other pre-specifiedEvaluation of Safety: Physical Examination

Physical examination data (covering the major body systems; general appearance, head \[ear, nose and throat\], cardiovascular, eyes, respiratory, abdomen, urogenital, musculoskeletal, neurological, lymph nodes and skin) were categorized as "normal"; "abnormal, not clinically significant;" "abnormal, clinically significant" or "not done". Physical examinations were performed at Screening, then at the Last day in ICU and Day 28 (Out of ICU) or Early Termination, from which the last observation performed is derived. The changes from baseline to the last observations performed are categorized as "no change", "change clinically significant"; "change not clinically significant", "not done".

Time frame:
From baseline to Last Observation Performed (D28 or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)
Reported as:
Count of participants · Participants
Evaluation of Safety: Physical Examination
ParticipantsFP-1201-lyo 10 μgPlacebo
General Appearance — No change5966
General Appearance — Change, Clinically Significant89
General Appearance — Change, Not Clinically Significant88
General Appearance — Not done3334
General Appearance — Not available/pt died3635
Ear, Nose and Throat — No change6775
Ear, Nose and Throat — Change, Clinically Significant21
Ear, Nose and Throat — Change, Not Clinically Significant56
Ear, Nose and Throat — Not done3435
Ear, Nose and Throat — Not available/pt died3635
Eyes — No change7076
Eyes — Change, Clinically Significant11
Eyes — Change, Not Clinically Significant23
Eyes — Not done3536
Eyes — Not available/pt died3636
Respiratory — No change2730
Respiratory — Change, Clinically Significant3028
Respiratory — Change, Not Clinically Significant2126
Respiratory — Not done3033
Respiratory — Not available/pt died3635
Abdomen — No change6570
Abdomen — Change, Clinically Significant32
Abdomen — Change, Not Clinically Significant910
Abdomen — Not done3135
Abdomen — Not available/pt died3635
Urogenital — No change6772
Urogenital — Change, Clinically Significant33
Urogenital — Change, Not Clinically Significant64
Urogenital — Not done3238
Urogenital — Not available/pt died3635
Musculoskeletal — No change5963
Musculoskeletal — Change, Clinically Significant118
Musculoskeletal — Change, Not Clinically Significant59
Musculoskeletal — Not done3337
Musculoskeletal — Not available/pt died3635
Neurological — No change4955
Neurological — Change, Clinically Significant1814
Neurological — Change, Not Clinically Significant813
Neurological — Not done3334
Neurological — Not available/pt died3636
Lymph nodes — No change6978
Lymph nodes — Change, Clinically Significant00
Lymph nodes — Change, Not Clinically Significant00
Lymph nodes — Not done3939
Lymph nodes — Not available/pt died3635
Skin — No change6464
Skin — Change, Clinically Significant38
Skin — Change, Not Clinically Significant58
Skin — Not done3637
Skin — Not available/pt died3635
Cardiovascular — No change5660
Cardiovascular — Change, Clinically Significant98
Cardiovascular — Change, Not Clinically Significant812
Cardiovascular — Not done3337
Cardiovascular — Not available/pt died3835
Other pre-specifiedEvaluation of Safety: Laboratory Results

Laboratory safety assessments of biochemistry, haematology and urinalysis were performed daily during the stay at ICU. Laboratory data were classified according to normal ranges as out of range (OOR; not clinically significant), OOR (clinically significant), or OOR (clinically significant and an AE). Laboratory test results were summarised by actual results by baseline and last observation period.

Time frame:
From baseline to Day 28 (or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)
Reported as:
Count of participants · Participants
Evaluation of Safety: Laboratory Results
ParticipantsFP-1201-lyo 10 μgPlacebo
Haemoglobin, Pre-Dose — Normal2230
Haemoglobin, Pre-Dose — OOR (NCS)103107
Haemoglobin, Pre-Dose — OOR (CS)1914
Haemoglobin, Pre-Dose — OOR (CS+AE)00
Haemoglobin, Pre-Dose — Not available/pt died01
Haemoglobin, LOP — Normal1718
Haemoglobin, LOP — OOR (NCS)100117
Haemoglobin, LOP — OOR (CS)2316
Haemoglobin, LOP — OOR (CS+AE)31
Haemoglobin, LOP — Not available/pt died10
Platelets, Pre-Dose — Normal8591
Platelets, Pre-Dose — OOR (NCS)4342
Platelets, Pre-Dose — OOR (CS)1617
Platelets, Pre-Dose — OOR (CS+AE)00
Platelets, Pre-Dose — Not available/pt died02
Platelets, LOP — Normal7665
Platelets, LOP — OOR (NCS)5272
Platelets, LOP — OOR (CS)1010
Platelets, LOP — OOR (CS+AE)55
Platelets, LOP — Not available/pt died10
Leucocytes, Pre-Dose — Normal4058
Leucocytes, Pre-Dose — OOR (NCS)7256
Leucocytes, Pre-Dose — OOR (CS)3236
Leucocytes, Pre-Dose — OOR (CS+AE)00
Leucocytes, Pre-Dose — Not available/pt died02
Leucocytes, LOP — Normal7257
Leucocytes, LOP — OOR (NCS)5270
Leucocytes, LOP — OOR (CS)1521
Leucocytes, LOP — OOR (CS+AE)34
Leucocytes, LOP — Not available/pt died20
Albumin, Pre-Dose — Normal1717
Albumin, Pre-Dose — OOR (NCS)83106
Albumin, Pre-Dose — OOR (CS)2014
Albumin, Pre-Dose — OOR (CS+AE)00
Albumin, Pre-Dose — Not available/pt died2415
Albumin, LOP — Normal2625
Albumin, LOP — OOR (NCS)97117
Albumin, LOP — OOR (CS)189
Albumin, LOP — OOR (CS+AE)10
Albumin, LOP — Not available/pt died21
Creatine Kinase, Pre-Dose — Normal5962
Creatine Kinase, Pre-Dose — OOR (NCS)3245
Creatine Kinase, Pre-Dose — OOR (CS)1911
Creatine Kinase, Pre-Dose — OOR (CS+AE)10
Creatine Kinase, Pre-Dose — Not available/pt died3334
Creatine Kinase, LOP — Normal8293
Creatine Kinase, LOP — OOR (NCS)4545
Creatine Kinase, LOP — OOR (CS)118
Creatine Kinase, LOP — OOR (CS+AE)20
Creatine Kinase, LOP — Not available/pt died46
Creatinine, Pre-Dose — Normal7872
Creatinine, Pre-Dose — OOR (NCS)4150
Creatinine, Pre-Dose — OOR (CS)2328
Creatinine, Pre-Dose — OOR (CS+AE)20
Creatinine, Pre-Dose — Not available/pt died02
Creatinine, LOP — Normal6973
Creatinine, LOP — OOR (NCS)5664
Creatinine, LOP — OOR (CS)1314
Creatinine, LOP — OOR (CS+AE)51
Creatinine, LOP — Not available/pt died10
Glucose, Pre-Dose — Normal5653
Glucose, Pre-Dose — OOR (NCS)7685
Glucose, Pre-Dose — OOR (CS)1110
Glucose, Pre-Dose — OOR (CS+AE)00
Glucose, Pre-Dose — Not available/pt died14
Glucose, LOP — Normal6574
Glucose, LOP — OOR (NCS)7175
Glucose, LOP — OOR (CS)73
Glucose, LOP — OOR (CS+AE)00
Glucose, LOP — Not available/pt died10
Bilirubin, Pre-Dose — Normal88106
Bilirubin, Pre-Dose — OOR (NCS)3733
Bilirubin, Pre-Dose — OOR (CS)96
Bilirubin, Pre-Dose — OOR (CS+AE)00
Bilirubin, Pre-Dose — Not available/pt died107
Bilirubin, LOP — Normal114121
Bilirubin, LOP — OOR (NCS)1923
Bilirubin, LOP — OOR (CS)43
Bilirubin, LOP — OOR (CS+AE)65
Bilirubin, LOP — Not available/pt died10
AST, Pre-Dose — Normal5752
AST, Pre-Dose — OOR (NCS)5070
AST, Pre-Dose — OOR (CS)1814
AST, Pre-Dose — OOR (CS+AE)20
AST, Pre-Dose — Not available/pt died1716
AST, LOP — Normal6776
AST, LOP — OOR (NCS)5456
AST, LOP — OOR (CS)811
AST, LOP — OOR (CS+AE)117
AST, LOP — Not available/pt died42
ALT, Pre-Dose — Normal8692
ALT, Pre-Dose — OOR (NCS)3743
ALT, Pre-Dose — OOR (CS)99
ALT, Pre-Dose — OOR (CS+AE)20
ALT, Pre-Dose — Not available/pt died108
ALT, LOP — Normal7285
ALT, LOP — OOR (NCS)5246
ALT, LOP — OOR (CS)812
ALT, LOP — OOR (CS+AE)108
ALT, LOP — Not available/pt died21
Bicarbonate, Pre-Dose — Normal9097
Bicarbonate, Pre-Dose — OOR (NCS)4447
Bicarbonate, Pre-Dose — OOR (CS)87
Bicarbonate, Pre-Dose — OOR (CS+AE)00
Bicarbonate, Pre-Dose — Not available/pt died21
Bicarbonate, LOP — Normal89105
Bicarbonate, LOP — OOR (NCS)4741
Bicarbonate, LOP — OOR (CS)76
Bicarbonate, LOP — OOR (CS+AE)00
Bicarbonate, LOP — Not available/pt died10
Urine Protein, Pre-Dose — Normal5254
Urine Protein, Pre-Dose — OOR (NCS)6773
Urine Protein, Pre-Dose — OOR (CS)57
Urine Protein, Pre-Dose — OOR (CS+AE)00
Urine Protein, Pre-Dose — Not available/pt died2018
Urine Protein, LOP — Normal6684
Urine Protein, LOP — OOR (NCS)6353
Urine Protein, LOP — OOR (CS)107
Urine Protein, LOP — OOR (CS+AE)01
Urine Protein, LOP — Not available/pt died57
Urine Glucose, Pre-Dose — Normal114123
Urine Glucose, Pre-Dose — OOR (NCS)97
Urine Glucose, Pre-Dose — OOR (CS)03
Urine Glucose, Pre-Dose — OOR (CS+AE)00
Urine Glucose, Pre-Dose — Not available/pt died2119
Urine Glucose, LOP — Normal128135
Urine Glucose, LOP — OOR (NCS)910
Urine Glucose, LOP — OOR (CS)10
Urine Glucose, LOP — OOR (CS+AE)00
Urine Glucose, LOP — Not available/pt died67
Urine Blood, Pre-Dose — Normal4853
Urine Blood, Pre-Dose — OOR (NCS)6775
Urine Blood, Pre-Dose — OOR (CS)108
Urine Blood, Pre-Dose — OOR (CS+AE)00
Urine Blood, Pre-Dose — Not available/pt died1916
Urine Blood, LOP — Normal5758
Urine Blood, LOP — OOR (NCS)7377
Urine Blood, LOP — OOR (CS)910
Urine Blood, LOP — OOR (CS+AE)00
Urine Blood, LOP — Not available/pt died57
Other pre-specifiedEvaluation of Pharmacoeconomics: Days Free of Organ Failure

Due to the study terminating early, costs items from hospitals were not collected and pharmacoeconomic analyses could not be done.

Time frame:
Day 28 (or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)

No measurements were reported for this outcome.

Other pre-specifiedEvaluation of Pharmacoeconomics: Days Free of Renal Support

Due to the study terminating early, costs items from hospitals were not collected and pharmacoeconomic analyses could not be done.

Time frame:
Day 28 (or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)

No measurements were reported for this outcome.

Other pre-specifiedEvaluation of Pharmacoeconomics: Days Free of Vasoactive Support

Due to the study terminating early, costs items from hospitals were not collected and pharmacoeconomic analyses could not be done.

Time frame:
Day 28 (or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)

No measurements were reported for this outcome.

Other pre-specifiedEvaluation of Pharmacoeconomics: Days Free of Mechanical Ventilation

Due to the study terminating early, costs items from hospitals were not collected and pharmacoeconomic analyses could not be done.

Time frame:
Day 28 (or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)

No measurements were reported for this outcome.

Other pre-specifiedEvaluation of Pharmacoeconomics: Number of ICU-free Days

Due to the study terminating early, costs items from hospitals were not collected and pharmacoeconomic analyses could not be done.

Time frame:
Day 28 (or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)

No measurements were reported for this outcome.

Other pre-specifiedEvaluation of Pharmacoeconomics: Number of Days in Hospital

Due to the study terminating early, costs items from hospitals were not collected and pharmacoeconomic analyses could not be done.

Time frame:
Day 28 (or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)

No measurements were reported for this outcome.

Other pre-specifiedExploratory Variables Relating to Efficacy: Composite Endpoint (Mortality and Days Free of Mechanical Ventilation) at Day 90

Composite endpoint including mortality and days free of mechanical ventilation (VFDsurv) within 90 days among survivors. Ventilation Free Survival at Day 90 has been classified as Dead, Alive but on a ventilator and Alive and breathing unassisted

Time frame:
Within 90 days
Reported as:
Count of participants · Participants
Exploratory Variables Relating to Efficacy: Composite Endpoint (Mortality and Days Free of Mechanical Ventilation) at Day 90
ParticipantsFP-1201-lyo 10 μgPlacebo
Dead4748
Alive-on ventilator610
Alive-breathing unassisted9091
Other pre-specifiedChange in the Treatment-specific Exploratory Biomarker Cluster of Differentiation 73 (CD73) Concentration

Evaluation of Cluster of differentiation 73 (CD73) change from baseline to D14 between treatments arms over time.

Time frame:
From baseline to Day 14
Reported as:
Mean · ng/ml
Change in the Treatment-specific Exploratory Biomarker Cluster of Differentiation 73 (CD73) Concentration
ng/mlFP-1201-lyo 10 μgPlacebo
Change in the Treatment-specific Exploratory Biomarker Cluster of Differentiation 73 (CD73) Concentration6.2 ± 8.96.1 ± 7.9
Other pre-specifiedChanges in Levels of Potential Inflammatory Markers (PIMs)

Evaluation of potential inflammatory markers (PIMs) change from baseline to D14 between treatments arms over time. Potential biomarkers included IL-1ra, IL-6, FGF basic, IP-10 and TNF-α.

Time frame:
From baseline to Day 14
Reported as:
Mean · pg/mL
Changes in Levels of Potential Inflammatory Markers (PIMs)
pg/mLFP-1201-lyo 10 μgPlacebo
IL-1ra1830 ± 52521699 ± 4565
IL-663 ± 29888 ± 584
FGF basic37 ± 1738 ± 20
IP-101938 ± 35431762 ± 3894
TNF-α68 ± 6081 ± 148
Statistical analysis
  • FP-1201-lyo 10 μg · ANCOVA · p = >0.05 · Ls means difference: 0ANCOVA estimates (LS means and a 95 % CI for the treatment difference) were presented for all numeric biomarker variables.
  • FP-1201-lyo 10 μg · ANCOVA · p = >0.05 · Ls means difference: 0ANCOVA estimates (LS means and a 95 % CI for the treatment difference) were presented for all numeric biomarker variables.
  • FP-1201-lyo 10 μg · ANCOVA · p = <0.05 · Ls means difference: 0ANCOVA estimates (LS means and a 95% CI for the treatment difference) were presented for all numeric biomarker variables.
  • FP-1201-lyo 10 μg · ANCOVA · p = <0.05 · Ls means difference: 0ANCOVA estimates (LS means and a 95 % CI for the treatment difference) were presented for all numeric biomarker variables.
  • FP-1201-lyo 10 μg · ANCOVA · p = >0.05 · Ls means difference: 0ANCOVA estimates (LS means and a 95 % CI for the treatment difference) were presented for all numeric biomarker variables.
Other pre-specifiedPharmacogenetic Analysis

An optional genetic sample was analysed for subjects based on a separate consent. A carrier frequency was analysed for a C/T polymorphism (rs9984723) located in the 3'PRIME_UTR/intron region of IFNAR2-gene, which encodes the beta chain for the IFN-alpha/beta receptor and encompasses a regulatory motif for the glucocorticoid receptor. Biomarker responders were defined by a 3-fold elevation in MxA and a 2-fold in CD73 in comparison to baseline.

Time frame:
Anytime from baseline to Day 28
Reported as:
Count of participants · Participants
Pharmacogenetic Analysis
ParticipantsBiomarker ResponderBiomarker Non-responder
C-allele carrier2126
C-allele non-carrier1247
Statistical analysis
  • Biomarker Responder · Chi-squared · p = <0.007 (The p-value is not adjusted for multiple comparisons.)
Other pre-specifiedExploratory, Extended Long-term Follow-up: Overall Mortality at Day 360

Fatalities; as the study was terminated early, the assessment time point for mortality at Day 360 was not reached. Therefore only the overall mortality at study termination is presented.

Time frame:
Day 360 /termination of study
Reported as:
Count of participants · Participants
Exploratory, Extended Long-term Follow-up: Overall Mortality at Day 360
ParticipantsFP-1201-lyo 10 μgPlacebo
Exploratory, Extended Long-term Follow-up: Overall Mortality at Day 3605153
Other pre-specifiedExtended Long-term Follow-up Exploratory Endpoint: Change in Quality of Life From Baseline to Day 360

Quality of Life was assessed through EQ-5D-3L (EuroQol 5-Dimensions 3-Levels questionnaire). An EQ Visual Analogue Scale (VAS) total score (ranging from 0-100) was measured (0= Worst imaginable health state, 100= Best imaginable health state). The EQ-5D-3L VAS scores are numerically summarised as change from pre-dose (Day 1) to extended long term follow-up (Day 360 visit).

Time frame:
Change from baseline to Day 360
Reported as:
Median · change score on a scale
Extended Long-term Follow-up Exploratory Endpoint: Change in Quality of Life From Baseline to Day 360
change score on a scaleFP-1201-lyo 10 μgPlacebo
Extended Long-term Follow-up Exploratory Endpoint: Change in Quality of Life From Baseline to Day 3600 (-59 to 35)0 (-80 to 86)
Other pre-specifiedNeurological Functioning (6MWT) at Extended Long-term Follow-up

The 6-minute walk test (6MWT) measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes. According to the ERS/ATS technical standard to which the 6MWT was done, the walk test is done twice and the best result is used. It is an evaluation of the global and integrated responses of all systems involved during exercise, including the pulmonary and cardiovascular systems, systemic circulation, peripheral circulation, blood and neuromuscular units and muscle metabolism. The self-paced 6MWT assesses the sub- maximal level of functional capacity and will better reflect the functional exercise level for daily activities. ANOVA parameters estimates (LS Means and 90 % confidence intervals) for the overall treatment difference was analysed.

Time frame:
Day 360
Reported as:
Mean · maximal distance walked (meters)
Neurological Functioning (6MWT) at Extended Long-term Follow-up
maximal distance walked (meters)FP-1201-lyo 10 μgPlacebo
Neurological Functioning (6MWT) at Extended Long-term Follow-up475 ± 119453 ± 190
Statistical analysis
  • FP-1201-lyo 10 μg vs Placebo · ANOVA · p = >0.05 · Least squares mean: 28 · 95% CI -54 to 110.1
Other pre-specifiedExtended Long-term Follow-up Endpoint: Respiratory Functioning (FEV1) at Day 360

Measuring FEV1 (forced expiratory volume in 1 second) assessed pulmonary function (airway obstruction, bronchoconstriction or bronchodilation). FEV1 is the volume exhaled during the first second of a forced expiratory manoeuvre, starting from the level of total lung capacity.

Time frame:
Day 360
Reported as:
Mean · %FEV1
Extended Long-term Follow-up Endpoint: Respiratory Functioning (FEV1) at Day 360
%FEV1FP-1201-lyo 10 μgPlacebo
Extended Long-term Follow-up Endpoint: Respiratory Functioning (FEV1) at Day 36069.4 ± 31.872.0 ± 28.5
Post-hocPost-Hoc Analyses Related to the Use of Concomitant Glucocorticoids Medications and Mortality at D28

The overall use of concomitant glucocorticoids treatment in both study treatment groups (active and placebo) were analysed.

Time frame:
Day 28
Reported as:
Number · percentage of participants
Post-Hoc Analyses Related to the Use of Concomitant Glucocorticoids Medications and Mortality at D28
percentage of participantsFP-1201-lyo 10 μgPlacebo
Use of concomitant glucocorticoids54.164.5
Mortality, with concomitant glucocorticoids39.727.6
Mortality, without concomitant glucocorticoids10.614.8

Adverse events

Collected over The Adverse Event (AE) reporting period extended up to study Day 28. In accordance with the protocol, the investigators reported AEs occurring after Day 28 only if the investigator considered a causal relationship with the study drug. All deaths were reported as SAEs throughout the study, up until Day 360.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FP-1201-lyo 10 μg51/144 (35.4%)77/144 (53.5%)109/144 (75.7%)
Placebo53/152 (34.9%)77/152 (50.7%)110/152 (72.4%)
Most frequent serious events
Showing 10 of 126
Most frequent serious events
EventFP-1201-lyo 10 μgPlacebo
MULTI-ORGAN FAILUREGeneral disorders13/1448/152
CONDITION AGGRAVATEDGeneral disorders7/14411/152
RESPIRATORY FAILURERespiratory, thoracic and mediastinal disorders3/1449/152
PNEUMONIAInfections and infestations5/1449/152
SEPTIC SHOCKInfections and infestations7/1445/152
ACUTE RESPIRATORY DISTRESS SYNDROMERespiratory, thoracic and mediastinal disorders2/1447/152
SHOCK HAEMORRHAGICVascular disorders6/1442/152
HYPOXIARespiratory, thoracic and mediastinal disorders4/1446/152
CARDIAC ARRESTCardiac disorders4/1445/152
ACUTE KIDNEY INJURYRenal and urinary disorders1/1445/152
Most frequent other events
Showing 10 of 332
Most frequent other events
EventFP-1201-lyo 10 μgPlacebo
PYREXIAGeneral disorders17/14412/152
ANAEMIABlood and lymphatic system disorders16/14411/152
ATRIAL FIBRILLATIONCardiac disorders9/14415/152
CONSTIPATIONGastrointestinal disorders11/14414/152
HYPERTENSIONVascular disorders11/14410/152
HYPERNATRAEMIAMetabolism and nutrition disorders9/1447/152
HEPATOCELLULAR INJURYHepatobiliary disorders9/1448/152
PNEUMONIAInfections and infestations8/1444/152
SEPSISInfections and infestations8/1443/152
PLEURAL EFFUSIONRespiratory, thoracic and mediastinal disorders8/1444/152

Baseline characteristics

A total of 296 subjects received at least 1 dose of study treatment (301 subjects fulfilled all criteria and were randomly assigned in a 1:1 ratio to FP-1201-lyo and placebo, but 5 subjects were not dosed).The Full Analysis Set (FAS) consisted of the 296 randomised and treated subjects who received 1 or more doses study medication.

Age, Categorical
Age, Categorical(Participants)FP-1201-lyo 10 μgPlaceboTotal
<=18 years000
Between 18 and 65 years89101190
>=65 years5551106
Age, Continuous
Age, Continuous(years)FP-1201-lyo 10 μgPlaceboTotal
Mean58.3 ± 17.258.4 ± 14.058.4 ± 15.6
Sex: Female, Male
Sex: Female, Male(Participants)FP-1201-lyo 10 μgPlaceboTotal
Female4261103
Male10291193
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)FP-1201-lyo 10 μgPlaceboTotal
Race — American Indian/Alaskan112
Race — Native Arab426
Race — Asian-Other123
Race — Black459
Race — Other or not reported353671
Race — White99106205
Region of Enrollment
Region of Enrollment(Participants)FP-1201-lyo 10 μgPlaceboTotal
Belgium121224
Czechia112
Finland151530
Italy181937
United Kingdom252954
France5458112
Germany8715
Spain111122
08

Study locations

71 sites
  • Erasmus Hospital
    Brussels, B-1070, Belgium
  • UZ Brussel
    Brussels, B-1090, Belgium
  • UZ Antwerpen
    Edegem, B-2650, Belgium
  • UZ Gent
    Gent, B-9000, Belgium
  • CHU Charleroi Site Hôpital Civil Marie Curie
    Lodelinsart, B-6042, Belgium
  • CHU Dinant Godinne UCL Namur
    Yvoir, B-5530, Belgium
  • Fakultni nemocnice Hradec Kralove
    Hradec Králové, 50005, Czechia
  • Fakultni nemocnice Kralovske Vinohrady
    Praha 10, 10034, Czechia
  • Hospital Usti nad Labem
    Usti nad Labem, 40011, Czechia
  • Helsinki University Hospital
    Helsinki, FI-00290, Finland
  • Kuopio University Hospital
    Kuopio, FI-70210, Finland
  • Tampere University Hospital
    Tampere, FI-33521, Finland
  • Turku University Central Hospital
    Turku, 20520, Finland
  • Nouvel Hôpital Civil
    Strasbourg, Alsace 67091, France
  • Centre Hospitalier Régional d'Orléans
    Orléans, Loiret 45067, France
  • CHU D'Angers
    Angers, Pays-de-la-Loire 49100, France
  • CHU De Poitiers
    Poitiers, Poitou-Charentes 86021, France
  • Hôpital de la Croix Rousse
    Lyon, Rhône 69004, France
  • Hôpital Charles-Nicolle
    Rouen, Seine-Maritime 76038, France
  • CHU Cavale Blanche
    Brest, 29609, France
  • Centre Hospitalier Universitaire de Bicêtre
    Le Kremlin-Bicêtre, 94270, France
  • Centre Hospitalier Le Mans
    Le Mans, 35033, France
  • Hôpital Nord AP-HM
    Marseille, 13015, France
  • CHRU Nancy
    Nancy, 54000, France
  • Pitié-Salpêtrière Hospital
    Paris, 75013, France
  • CHU Pontchaillou
    Rennes, 35033, France
  • CHU Bretonneau
    Tours, 37044, France
  • Hôpital Cochin, Réanimation Médicale Hospitalisation
    Paris, Île-de-France 75014, France
  • Klinikum Augsburg Klinik für Anästhesiologie
    Augsburg, 86156, Germany
  • Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum
    Berlin, 13353, Germany
  • Universitätsklinikum Bonn Klinik und Poliklinik für Anästhesiologie
    Bonn, 53127, Germany
  • Universitätsklinikum Carl Gustav Carus Klinik für Anästhesiologie und Intensivmedizin
    Dresden, 01307, Germany
  • Universitätsmedizin Göttingen Klinik für Anästhesiologie
    Göttingen, 37075, Germany
  • Universitätsklinikum Hamburg-Eppendorf Klinik für Intesivmedizin
    Hamburg, 20246, Germany
  • Kliniken der Stadt Köln Klinikum Merheim
    Köln, 51109, Germany
  • Universitätsklinik Leipzig Klinik und Poliklinik für Anäesthesiologie und Intensivtherapie
    Leipzig, 04103, Germany
  • Azienda Ospedaliera Universitaria Sant' Anna
    Cona, 44124, Italy
  • IRCCS Ca' Granda Ospedale Maggiore Policlinico
    Milano, 20122, Italy
  • ASST Monza
    Monza, 209000, Italy
  • Universita degli Studi di Roma "La Sapienza"
    Roma, 00161, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli
    Roma, 00168, Italy
  • AOU Città della Salute e della Scienza di Torino
    Torino, 10126, Italy
  • Hospital Universitario Germans Trias i Pujol
    Badalona, 08916, Spain
  • Hospital del Mar
    Barcelona, 08003, Spain
  • Hospital de la Santa Creu I Sant Pau
    Barcelona, 08026, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Clínic i Provincial de Barcelona
    Barcelona, 08036, Spain
  • Hospital Universitario del Henares
    Coslada, 28822, Spain
  • Hospital Universitario de Getafe
    Getafe, 28905, Spain
  • Hospital Universitario de Gran Canaria Dr Negrin
    Las Palmas de Gran Canaria, 35010, Spain
  • Hospital Universitario La Paz
    Madrid, 28007, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Universitari Son Espases
    Palma De Mallorca, 07120, Spain
  • Corporació Sanitària Parc Taulí
    Sabadell, 08208, Spain
  • Hospital Universitari Mútua de Terrassa
    Terrassa, 08221, Spain
  • Hospital Universitari i Politecnic La Fe de Valencia
    Valencia, 46026, Spain
  • Hospital Universitario Rio Hortega
    Valladolid, 47012, Spain
  • Bristol Royal Infirmary University Hospitals, Bristol Foundation Trust
    Bristol, BS2 8HW, United Kingdom
  • University Hospital of Wales
    Cardiff, CF14 4XW, United Kingdom
  • Royal Infirmary of Edinburgh
    Edinburgh, EH16 4SA, United Kingdom
  • University College London Hospitals, NHS Foundation Trust
    London, NW1 2BU, United Kingdom
  • Guy's and St Thomas' NHS Foundation Trust
    London, SE1 7EH, United Kingdom
  • King's College Hospital NHS Foundation Trust
    London, SE5 9RS, United Kingdom
  • St George's University Hospitals, NHS Foundation Trust
    London, SW17 0QT, United Kingdom
  • Hammersmith Hospital Imperial College Healthcre NHS Trust
    London, W12 0HS, United Kingdom
  • Charing Cross Hospital St Mary's Hospital, Imperial College Healthcare NHS Trust
    London, W21NY, United Kingdom
  • Charing Cross Hospital Imperial College Healthcare NHS Trust
    London, W6 8RF, United Kingdom
  • Norfolk and Norwich University Hospitals NHS Foundation Trust
    Norwich, NR4 7UY, United Kingdom
  • Nottingham University Hospitals NHS Trust
    Nottingham, NG7 2UH, United Kingdom
  • Lancashire Treaching Hospitals NHS Foundation Trust
    Preston, PR2 9HT, United Kingdom
  • Southampton General Hospital, University Hospital Southampton NHS Foundation Trust
    Southampton, SO16 6YD, United Kingdom
09

References and documents

Publications

  • Ranieri VM, Pettila V, Karvonen MK, Jalkanen J, Nightingale P, Brealey D, Mancebo J, Ferrer R, Mercat A, Patroniti N, Quintel M, Vincent JL, Okkonen M, Meziani F, Bellani G, MacCallum N, Creteur J, Kluge S, Artigas-Raventos A, Maksimow M, Piippo I, Elima K, Jalkanen S, Jalkanen M, Bellingan G; INTEREST Study Group. Effect of Intravenous Interferon beta-1a on Death and Days Free From Mechanical Ventilation Among Patients With Moderate to Severe Acute Respiratory Distress Syndrome: A Randomized Clinical Trial. JAMA. 2020 Feb 25;323(8):725-733. doi: 10.1001/jama.2019.22525. PubMed 32065831 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2015 to primary completion in May 2018, 28 months.

Results were first posted in Mar 2020, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2015
First posted
Dec 4, 2015
StartActual
Dec 23, 2015
Primary completionActual
May 17, 2018
CompletionActual
May 23, 2018
Results first posted
Mar 30, 2020
Last update
Mar 30, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02622724
Lead sponsor
Faron Pharmaceuticals Ltd
Collaborators
Seventh Framework Programme
Responsible party
Sponsor
First posted
Dec 4, 2015
Start date
Dec 23, 2015
Primary completion
May 17, 2018
Completion
May 23, 2018
Results posted
Mar 30, 2020
Last update
Mar 30, 2020

Study contacts

Geoffrey Bellingan, MD
study director · University College London Hospitals, NHS, London, UK
V Marco Ranieri, Prof. MD
study director · Universita La Sapeinza Policlinico Umberto I, Rome, Italy

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Interferon beta-1a

Start the discussion